脂质体紫杉醇联合奈达铂治疗对NSCLC血清miR-4731-3p与miR-21的影响及意义

为探讨紫杉醇脂质体联合奈达铂治疗非小细胞肺癌(NSCLC)的效果及对患者血中miR-4731-3p、miR-21的影响。选取本院收治的96例晚期NSCLC患者,其中48例采用紫杉醇脂质体联合奈达铂治疗(试验组)、另外48例患者采用紫杉醇联合奈达铂治疗(对照组),对比两组患者的化疗效果。结果显示,试验组的完全缓解率和部分缓解率(64.6%)高于对照组(43.7%)(P<0.05),且miR-4731-3p、miR-21水平显著低于对照组(P<0.05)；随访24个月, 试验组患者的中位生存时间21个月高于对照组的18个月(Log-Rank(Mantel-Cox)=5.321,P=0.021)。提示紫杉醇脂质体联合奈达铂治疗晚期NSCLC的效果优于紫杉醇联合奈达铂,同时能有效降低miR-4731-3p、miR-21水平。

Effect of liposomal paclitaxel combined with nedaplatin on serum miR-4731-3p and miR-21 in NSCLC

To investigate the effect of paclitaxel liposome combined with nedaplatin on NSCLC and the effects of miR-4731-3p and serum miR-21 in plasma. Ninety-six patients with advanced NSCLC were enrolled in our hospital, 48 of whom were treated with paclitaxel liposome plus nedaplatin (test group) and 48 patients were treated with paclitaxel plus nedaplatin (control group). Chemotherapy effect was compared. The results showed that the rate of complete remission and partial remission of the test group was (64.6%) higher than that of the control group (43.7%) (P<0.05), and the levels of miR-4731-3p and miR-21 were significantly lower than the control group (P<0.05). During the follow-up of 24 months, the median survival time of the test group was 21 months higher than that of the control group (Log-Rank (Mantel-Cox)=5.321, P=0.021). It is suggested that paclitaxel liposome combined with nedaplatin is superior to paclitaxel combined with nedaplatin in the treatment of advanced NSCLC, and can effectively reduce miR-4731-3p and miR-21 levels.